Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUBOEX)

Drug Name
PMID29671355-Compound-23 Drug Info
Cross-matching ID
PubChem CID
118884610
TTD Drug ID
DMUBOEX

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Patented Agent(s)
Investigative Drug(s)
Clinical Trial Drug(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Histone deacetylase 5 (HDAC5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [1]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [1]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [1]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [1]
PMID29671355-Compound-67 DM1RPL4 N. A. N. A. Patented [1]
PMID29671355-Compound-45a DM5LYKR N. A. N. A. Patented [1]
TMP269 DMSMQE7 Discovery agent N.A. Investigative [3]
⏷ Show the Full List of 7 Drug(s)
Drug(s) Targeting Histone deacetylase 6 (HDAC6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Citarinostat DMQLODU Multiple myeloma 2A83 Phase 1 [4]
KA2507 DMW0H9Y Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [1]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [1]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [1]
PMID29671355-Compound-21 DMPJN0M N. A. N. A. Patented [1]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [1]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [1]
PMID29671355-Compound-67 DM1RPL4 N. A. N. A. Patented [1]
PMID29671355-Compound-44 DM80A3V N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histone deacetylase 8 (HDAC8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NBM-BMX DM5OWXA Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [1]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [1]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [1]
PMID29671355-Compound-21 DMPJN0M N. A. N. A. Patented [1]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [1]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [1]
PMID29671355-Compound-67 DM1RPL4 N. A. N. A. Patented [1]
PMID29671355-Compound-44 DM80A3V N. A. N. A. Patented [1]
PMID29671355-Compound-61 DMXH1G3 N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histone deacetylase 2 (HDAC2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CHR-3996 DMIXPNG Lymphoma 2A80-2A86 Phase 1/2 [6]
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [1]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [1]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [1]
PMID29671355-Compound-21 DMPJN0M N. A. N. A. Patented [1]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [1]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [1]
PMID29671355-Compound-67 DM1RPL4 N. A. N. A. Patented [1]
PMID29671355-Compound-44 DM80A3V N. A. N. A. Patented [1]
PMID29671355-Compound-61 DMXH1G3 N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histone deacetylase 4 (HDAC4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [1]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [1]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [1]
PMID29671355-Compound-21 DMPJN0M N. A. N. A. Patented [1]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [1]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [1]
PMID29671355-Compound-67 DM1RPL4 N. A. N. A. Patented [1]
PMID29671355-Compound-61 DMXH1G3 N. A. N. A. Patented [1]
PMID29671355-Compound-45a DM5LYKR N. A. N. A. Patented [1]
PMID29671355-Compound-68b DMLGBR6 N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histone deacetylase 1 (HDAC1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [7]
Romidepsin DMT5GNL Cutaneous T-cell lymphoma 2B01 Approved [8]
Panobinostat DM58WKG Chronic graft versus host disease Approved [7]
HBI-8000 DMDWYUN Non-small-cell lung cancer 2C25.Y Registered [9]
ITF2357 DMFZBNE Duchenne dystrophy 8C70 Phase 3 [10]
NVP-LAQ824 DM8JWNA Mood disorder 6A60-6E23 Phase 3 [11]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [12]
Phenylbutyrate DMBHPDW Urea cycle disorder 5C50.A Phase 2 [13]
MGCD-0103 DM726HX Non-small-cell lung cancer 2C25.Y Phase 2 [7]
Resminostat DMNE1FR Hepatocellular carcinoma 2C12.02 Phase 2 [14]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histone deacetylase 11 (HDAC11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [1]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [1]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [1]
PMID29671355-Compound-21 DMPJN0M N. A. N. A. Patented [1]
PMID29671355-Compound-44 DM80A3V N. A. N. A. Patented [1]
PMID29671355-Compound-36 DMQJ3TC N. A. N. A. Patented [1]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histone deacetylase 1 (HDAC1) TT6R7JZ HDAC1_HUMAN Inhibitor [1]
Histone deacetylase 11 (HDAC11) TT8K17W HDA11_HUMAN Inhibitor [1]
Histone deacetylase 2 (HDAC2) TTSHTOI HDAC2_HUMAN Inhibitor [1]
Histone deacetylase 4 (HDAC4) TTTQGH8 HDAC4_HUMAN Inhibitor [1]
Histone deacetylase 5 (HDAC5) TTUELN5 HDAC5_HUMAN Inhibitor [1]
Histone deacetylase 6 (HDAC6) TT5ZKDI HDAC6_HUMAN Inhibitor [1]
Histone deacetylase 8 (HDAC8) TTT6LFV HDAC8_HUMAN Inhibitor [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Tubulin alpha-4A chain OTWDBVZ4 TBA4A_HUMAN Post-Translational Modifications [2]

References

1 HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
2 Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3. Arch Toxicol. 2022 Jan;96(1):177-193. doi: 10.1007/s00204-021-03174-1. Epub 2021 Oct 19.
3 Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol. 2013 May;9(5):319-25.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of NatureWise Biotech & Medicals.
6 A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94.
7 Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
8 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
9 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
10 Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
11 NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
12 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
13 Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
14 2011 Pipeline of 4SC AG.